ReviewSeminars in immunology2021
Residual immune dysfunction under antiretroviral therapy.
Review in Seminars in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 65 citations in OpenAlex.
- Therapeutic HIV-1 Tat vaccination promotes durable immune reconstitution and reservoir reduction in ART-treated adults with clade C infection: a 12-year follow-up study.Frontiers in immunology · 2026Trial
- People with HIV on antiretroviral therapy demonstrate robust humoral response to influenza vaccination.AIDS research and therapy · 2026Article
- Serum Interleukin-6 and Interleukin-10 levels in people living with HIV on short-term and long-term antiretroviral therapy: a comparative cross-sectional study with HIV-negative controls.BMC infectious diseases · 2026Article
- CircRNA profiles of extracellular vesicle-enriched fractions from ART suppressed pregnant women living with HIV identifies interactome networks key to inflammation and viral latency.Journal of translational medicine · 2026Article
- Dengue-specific T-cell memory following natural infection: a comparative analysis between people living with HIV and HIV-negative individuals.Microbiology spectrum · 2026Observational
- The Gut-Immune Axis in Treated HIV Infection: From Mucosal Damage to Chronic Inflammation and Therapeutic Opportunities-A Clinician-Oriented Narrative Review.Microorganisms · 2026Review
- Impact of SARS-CoV-2 Breakthrough Infection on Short-Term CD4 Count Among Adults With HIV in the United States From 2020 to 2022.Open forum infectious diseases · 2026Article
- Distinct phases of immune system programming during ART-suppressed immunodeficiency virus infection.bioRxiv : the preprint server for biology · 2026Article
- Article
- Gut-heart immuno-metabolic disruption associated with inflammaging and subclinical coronary artery disease in people with HIV on antiretroviral therapy.Immunity & ageing : I & A · 2026Article
- Daily Consumption of Unprocessed/Minimally Processed Foods and Its Relationship with Serum Phosphorus, CD3+, and CD45+ Cell Counts in People Living with HIV: A Cross-Sectional Descriptive Study.Medical sciences (Basel, Switzerland) · 2026Article
- Dynamic changes of monocytes-related immune activation in people with HIV switching to long-acting injectable cabotegravir plus rilpivirine.Scientific reports · 2026Article
- Hepatitis B virus vaccination in people with HIV: what's new?Current opinion in HIV and AIDS · 2026Review
- Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir/emtricitabine/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in China.The Lancet regional health. Western Pacific · 2026Article
- Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.Nature medicine · 2026Article
- Exploratory Cohort Study of Depressive Symptoms in South Africans with HIV-1 Subtype C: Associations with Kynurenine Pathway Metabolites and Inflammatory Markers.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- Altered distribution of tissue galectins correlates with mucosal dysregulation in SIV infection.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Persistent immune dysfunction during suppressive antiretroviral therapy: implications for analytical treatment interruption trials for chronic HIV infections in sub-Saharan Africa.Frontiers in immunology · 2026Review
- JAK-STAT and IL-17 pathway dysregulation underlies persistent immune dysfunction in ART-experienced people living with HIV in Ghana.Frontiers in immunology · 2026Article
- Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The usage of combination antiretroviral therapy in people with HIV (PWH) has incited profound improvement in morbidity and mortality. Yet, PWH may not experience full restoration of immune function which can manifest with non-AIDS comorbidities that frequently associate with residual inflammation and can imperil quality of life or longevity. In this review, we discuss the pathogenesis underlying chronic inflammation and residual immune dysfunction in PWH, as well as potential therapeutic interventions to ameliorate them and prevent incidence or progression of non-AIDS comorbidities. Current evidence advocates that early diagnosis and prompt initiation of therapy at high CD4 counts may represent the best available approach for an improved immune recovery in PWH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.